Impact of pregnancy on progression of preclinical autoimmune disorders: a prospective cohort study
Main finding · Progression to definite autoimmune diseaseResult — go to the resultAdjusted odds ratio 4.9 95% CI 2.4–10Authors' conclusion
Among women with suspected autoimmune disease during pregnancy, additional viable pregnancies and diagnosis of preeclampsia were independently associated with an increased rate of progression to definite rheumatic disorder.
Study context
- Population
- Women with symptoms and laboratory findings suggestive of autoimmune disorder, enrolled in the first trimester of pregnancy
- Participants
- 208 women
- Exposure
- One or more subsequent viable pregnancies vs no subsequent pregnancies
- Subsequent pregnanciesn = 102
- No subsequent pregnanciesn = 106reference
- Outcome
- Progression to definite autoimmune (rheumatic) disease
- Follow-up
- 5 years
Methodological details5-year follow-up, multinomial logistic regression adjusted for confounders
- 5-year follow-up
- Multinomial logistic regression adjusted for confounders
Main finding
Progression to definite autoimmune disease
Adjusted odds ratio
4.9
95% CI 2.4–10
Events by group
Subsequent pregnanciesvs No subsequent pregnancies
aOR 4.9 (95% CI 2.4–10)
As reported in the abstract
Observational data: associations, not effects.
Further findings
Status at end of follow-up (all subjects) · 5 years
- Negative
- 81 (38.9%)
- Non-criteria rheumatic status
- 53 (25.5%)
- Definite rheumatic disease
- 74 (35.6%)
- Undifferentiated connective tissue disease
- 43
- SLE
- 5
- SS
- 3
- APS
- 10
- Miscellaneous autoimmune disorders
- 12
Time from enrolment to definite diagnosis
- Median, months (IQR 18-42)
- 28
Preeclampsia (index or subsequent pregnancy) as risk factor for progression to definite autoimmune disease
- aOR
- 4.3 (95% CI 1.2, 14.8)
- Additional and independent risk factor
Original publication
Impact of pregnancy on progression of preclinical autoimmune disorders: a prospective cohort study. Rheumatology (Oxford). Published 7 November 2022. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →